PMID- 31088240
OWN - NLM
STAT- MEDLINE
DCOM- 20200409
LR  - 20200409
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 11
IP  - 8
DP  - 2019 Jun
TI  - Rate of cancer progression as a predictive marker of efficacy of immunotherapy; 
      an analysis in metastatic non-small-cell lung cancer.
PG  - 657-665
LID - 10.2217/imt-2018-0180 [doi]
AB  - Aim: To explore the value of rate of cancer progression (ROP) prior to starting 
      PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: 
      Retrospective data of patients with metastatic non-small-cell lung cancer treated 
      with second-line PD-1 inhibitors were collected. Patients were divided into two 
      groups: slow and rapid based on their ROP. Results: A total of 73 patients were 
      eligible. Progression-free survival (PFS) was significantly shorter in rapid ROP, 
      compared with slow (1.7 vs 4.8 months; HR: 2.42; 95% CI: 1.36-4.30; p = 0.008), 
      as was the overall survival (OS; 5.6 vs 18.7 months; HR: 2.30; 95% CI: 1.13-4.69; 
      p = 0.02). Overall response rate (40 vs 17%) was numerically higher in slow ROP 
      than rapid (p = 0.19). PFS/OS did not correlate with the best response to their 
      last chemotherapy or time to progression from previous line of therapy. Presence 
      of a targetable mutation negatively correlated with PFS/OS. Conclusion: ROP prior 
      to starting PD-1 inhibitors correlates with survival. PFS/OS were shorter in 
      rapid ROP.
FAU - Prasanna, Thiru
AU  - Prasanna T
AD  - Medical Oncology Department, Chris O'Brien Lifehouse, New South Wales, Australia.
AD  - University Of Canberra, University Drive, Australian Capital Territory, 
      2617 Australia.
FAU - Arasaratnam, Mal
AU  - Arasaratnam M
AD  - Medical Oncology Department, Westmead hospital, New South Wales, Australia.
FAU - Boyer, Michael
AU  - Boyer M
AD  - Medical Oncology Department, Chris O'Brien Lifehouse, New South Wales, Australia.
AD  - Sydney Medical School, University of Sydney, New South Wales, Australia.
FAU - McNeil, Catriona
AU  - McNeil C
AD  - Medical Oncology Department, Chris O'Brien Lifehouse, New South Wales, Australia.
AD  - Sydney Medical School, University of Sydney, New South Wales, Australia.
FAU - Barnet, Megan B
AU  - Barnet MB
AD  - Garvan Institute, New South Wales, Australia.
AD  - The Kinghorn Cancer Centre, New South Wales, Australia.
FAU - Asher, Rebecca
AU  - Asher R
AD  - NHMRC Clinical Trials Centre, the University of Sydney, New South Wales, 
      Australia.
FAU - Hui, Rina
AU  - Hui R
AD  - Medical Oncology Department, Westmead hospital, New South Wales, Australia.
AD  - Sydney Medical School, University of Sydney, New South Wales, Australia.
FAU - Nagrial, Adnan
AU  - Nagrial A
AD  - Medical Oncology Department, Westmead hospital, New South Wales, Australia.
AD  - Sydney Medical School, University of Sydney, New South Wales, Australia.
FAU - Kao, Steven
AU  - Kao S
AD  - Medical Oncology Department, Chris O'Brien Lifehouse, New South Wales, Australia.
AD  - Sydney Medical School, University of Sydney, New South Wales, Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism/mortality
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/metabolism/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - PD-1 inhibitor
OT  - immunotherapy
OT  - lung cancer
OT  - predictive biomarker
OT  - rate of progression
EDAT- 2019/05/16 06:00
MHDA- 2020/04/10 06:00
CRDT- 2019/05/16 06:00
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/04/10 06:00 [medline]
AID - 10.2217/imt-2018-0180 [doi]
PST - ppublish
SO  - Immunotherapy. 2019 Jun;11(8):657-665. doi: 10.2217/imt-2018-0180.